Research programme: protein kinase inhibitors - TargeGen
Alternative Names: TG-100948; TG-101095; TG-101209Latest Information Update: 30 Aug 2011
At a glance
- Originator TargeGen
- Class Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Janus kinase 2 inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-ret inhibitors; Src-family kinase inhibitors; Vascular endothelial growth factor A inhibitors; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Age-related macular degeneration; Choroidal neovascularisation; Diabetic macular oedema; Myeloproliferative disorders; Retinal vascular occlusion
Most Recent Events
- 30 Aug 2011 No development reported - Preclinical for Age-related macular degeneration in USA (Topical)
- 30 Aug 2011 No development reported - Preclinical for Choroidal neovascularisation in USA (Topical)
- 30 Aug 2011 No development reported - Preclinical for Diabetic macular oedema in USA (Topical)